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Type I interferon (IFN-a/bor IFN-I) signals through two
receptor subunits, IFNAR1 and IFNAR2, to orches-
trate sterile and infectious immunity. Cellular path-
ways that regulate IFNAR1 are often targeted by
viruses to suppress the antiviral effects of IFN-I.
Herewe report that encephalitic flaviviruses, including
tick-borne encephalitis virus and West Nile virus,
antagonize IFN-I signaling by inhibiting IFNAR1 sur-
face expression. Loss of IFNAR1 was associated
with binding of the viral IFN-I antagonist, NS5, to
prolidase (PEPD), a cellular dipeptidase implicated in
primary immune deficiencies in humans. Prolidase
was required for IFNAR1 maturation and accumula-
tion, activation of IFNb-stimulated gene induction,
and IFN-I-dependent viral control. Human fibroblasts
derived from patients with genetic prolidase defi-
ciency exhibited decreased IFNAR1 surface expres-
sion and reduced IFNb-stimulated signaling. Thus,
by understanding flavivirus IFN-I antagonism, pro-
lidase is revealed as a central regulator of IFN-I
responses.
INTRODUCTION
Type I interferon (IFNa/b or IFN-I) elicits a potent signal via
the JAK-STAT signaling cascade to amplify innate immunity,
mobilize adaptive immunity, and curtail tumorigenesis (Gon-
za´lez-Navajas et al., 2012). However, uncontrolled signalingCby IFN-I is associated with a number of autoimmune condi-
tions including systemic lupus erythematosus (SLE), systemic
sclerosis, primary Sjogren’s syndrome, rheumatoid arthritis,
and psoriasis (Gonza´lez-Navajas et al., 2012). The IFN-I re-
ceptor (IFNAR) is expressed by nearly all cell types and is
composed of two subunits, IFNAR1 and IFNAR2 (de Weerd
and Nguyen, 2012). Ligation of IFNAR by IFN-I results in acti-
vation of the Janus kinases, Jak1 and Tyk2, that then phos-
phorylate signal transducer and activator of transcription
(STAT)-1 and STAT2, resulting in recruitment of IRF9 to form
the IFN-stimulated gene factor 3 (ISGF3) transcription factor.
ISGF3 translocates to the nucleus and binds to IFN-stimu-
lated response elements (ISREs) to drive transcription of hun-
dreds of IFN-stimulated genes (ISGs) (MacMicking, 2012). To
prevent aberrant gene expression, IFNAR expression is nega-
tively regulated through both ligand-dependent and -indepen-
dent mechanisms (Fuchs, 2013). Following IFN-I stimulation,
IFNAR1 is phosphorylated by Tyk2 and PKD2, leading to ubiq-
uitination and lysosomal degradation of IFNAR1 (Gauzzi et al.,
1997; Kumar et al., 2003; Zheng et al., 2011). Alternatively,
ligand-independent degradation occurs following IFNAR1
phosphorylation by p38 MAP kinase invoked by multiple
stimuli, including the PERK-dependent unfolded protein
response (UPR), ligation of pattern recognition receptors
(PRRs), or through signaling via other inflammatory cytokines
or growth factors including VEGF, IL-1b and TNFa (reviewed
in Fuchs, 2013).
Flaviviruses include tick-borne encephalitis virus (TBEV),
West Nile virus (WNV), and Japanese encephalitis virus (JEV),
which cause severe encephalitides in humans, as well as
dengue virus (DENV) and yellow fever virus (YFV), which cause
hemorrhagic fevers. These single-stranded RNA viruses are
highly sensitive to the antiviral effects of IFN-I if administeredell Host & Microbe 18, 61–74, July 8, 2015 ª2015 Elsevier Inc. 61
prior to infection, although the therapeutic potential of type I
IFN is limited by flavivirus-encoded strategies to evade IFN-
dependent signaling. As shown for WNV, JEV, and Langat virus
(LGTV; a member of the TBEV serogroup), some flaviviruses
antagonize IFN-I responses at a point proximal to the IFN-I
receptor, with all downstream signaling events leading to ISG
expression inhibited (Best et al., 2005; Guo et al., 2005; Lin
et al., 2006). In contrast, DENV and YFV inhibit the same
signaling cascade by degrading human STAT2 (Ashour et al.,
2009) or by preventing ISGF3 from binding DNA (Laurent-Rolle
et al., 2014), respectively. Despite these differences, all of these
flaviviruses utilize the nonstructural protein 5 (NS5) as a potent
IFN-I antagonist (Ashour et al., 2009; Best et al., 2005; Laurent-
Rolle et al., 2010, 2014). NS5 was originally identified as an
IFN-I suppressor from LGTV infection (Best et al., 2005) and
is the only protein shown by reverse genetics to impact flavivi-
rus resistance to the antiviral effects of IFN-I (Laurent-Rolle
et al., 2010, 2014). In the case of WNV, NS5 from the virulent
NY99 strain (WNVNY99) is a strong IFN-I antagonist while NS5
from the attenuated Kunjin strain (WNVKUN) is relatively ineffi-
cient. A single residue of WNV NS5 is responsible for these
differences, as mutation of WNVKUN at NS5 residue 653 to
WNVNY99 (S653F) increased viral IFN-I antagonism and resis-
tance to IFNb (Laurent-Rolle et al., 2010). Despite the impor-
tance of NS5 in immune evasion, the molecular mechanisms
by which it antagonizes JAK-STAT signaling are not well under-
stood, particularly for TBEV and WNV.
Prolidase (or pepdidase D; PEPD) is a metabolic enzyme
belonging to the metalloproteinase family responsible for hydro-
lysis of imidodipeptides containing C-terminal proline (Pro) or
hydroxyproline (HyPro) (Lupi et al., 2008). PEPD is important
for supplying Pro through the breakdown of dietary and endog-
enous proteins, particularly collagen (Surazynski et al., 2008b).
Prolidase deficiency (PD) is a rare autosomal-recessive disorder
associated with mutations in the human PEPD gene that is
usually diagnosed in early childhood. PD is phenotypically vari-
able but most often includes chronic skin lesions, developmental
delay, splenomegaly, recurrent pulmonary infections, immuno-
deficiencies, and, in the most severely affected patients,
pediatric death (Falik-Zaccai et al., 2010). Mechanisms of
immune deficiency include elevated immunoglobulin levels and
deficiency of the complement component, C1q. Approximately
10%of PD patients are diagnosedwith SLE or a lupus-like illness
(Falik-Zaccai et al., 2010; Kurien et al., 2013). However, the
molecular mechanisms underlying these immune abnormalities
are not known.
Here we investigate the mechanisms utilized by LGTV,
TBEV, and WNV to antagonize IFN-I signaling. We show that
IFNAR1 is selectively downregulated in cells infected with
these viruses and that this loss is associated with the function
of NS5 as an IFN-I antagonist. NS5 binds to PEPD, which is
required for NS5 to reduce IFNAR1. Using RNAi, we demon-
strate that PEPD is required for accumulation of IFNAR1
protein and ISG mRNA expression following IFNb stimulation.
Furthermore, examination of primary fibroblasts from PD
patients revealed low IFNAR1 accompanied by deficiencies
in IFN-I signaling, suggesting that PD is an unrecognized
primary immune deficiency associated with defects in innate
immunity.62 Cell Host & Microbe 18, 61–74, July 8, 2015 ª2015 Elsevier Inc.RESULTS
The Flaviviruses LGTV, TBEV, and WNV Downregulate
IFNAR1
NS5 derived from LGTV, TBEV, or WNV (strain NY99) is an effec-
tive inhibitor of IFN-I-mediated JAK-STAT signaling, although
the mechanism of inhibition remains enigmatic. Replication
of WNVNY99 is associated with loss of IFNAR1 (Evans et al.,
2011), implicating IFNAR1 as the target of viral interference.
However, the WNV protein responsible for depletion of IFNAR1
is not known. To further understand IFN-I antagonism, we deter-
mined if loss of IFNAR1 is a common feature of infection with
these viruses. IFNAR1 increased over time in mock-infected
cell cultures but was downregulated in cells infected with
LGTV (Figures 1A and S1A), coincident with increasing viral pro-
tein (NS5) expression and suppression of STAT1 tyrosine phos-
phorylation (pY-STAT1) following IFNb stimulation (Figure S1B).
IFNAR2 expression was not affected by LGTV infection (Fig-
ure 1B). A comparable reduction of IFNAR1 but not IFNAR2
was observed in cells infected with TBEV (Figure 1C). Thus,
infection by multiple flaviviruses is associated with reduced
expression of IFNAR1. However, downregulation of IFNAR1
appears to be independent of major degradation pathways as
treatment of LGTV-infected cells with inhibitors of lysosome-
(NH4Cl or Bafilomycin A1) or proteasome-mediated (MG132)
degradation did not rescue IFNAR1 (Figure S1C).
To determine if a role exists for NS5 in loss of IFNAR1, HEK293
cells were infected with wild-type (WT) WNVKUN where NS5
only partially blocks IFN-stimulated pY-STAT1, or with
WNVKUNS653F where NS5 efficiently inhibits pY-STAT1
similar to that of WNVNY99 (Laurent-Rolle et al., 2010). In
WNVKUNS653F-infected cells, reduction in cell surface IFNAR1
was evident by 40 hpi and complete by 48 hpi, whereas an effect
of WT WNVKUN on IFNAR1 was not apparent until 48 hpi (Fig-
ure 1D). The early loss of IFNAR1 was consistent with enhanced
antagonism of pY-STAT1 at 48 hpi with WNVKUNS653F following
stimulation with exogenously added IFNb (Figure 1E). The S653F
mutation confers an advantage to WNVKUN replication if IFN-I is
introduced early in the replication cycle (Laurent-Rolle et al.,
2010). However, the differences in IFNAR1 observed were not
attributable to differences in virus replication, which was indistin-
guishable between WT WNVKUN and WNVKUNS653F in the
absence of exogenously added IFN-I, consistent with our previ-
ous report (Laurent-Rolle et al., 2010) (Figure 1F). As IFN-I itself
negatively regulates IFNAR1 (Fuchs, 2013), increased produc-
tion of IFN-I byWNVKUNS653F could explain these results. How-
ever, no differences in IFNb production were observed at 48 hpi
when robust downregulation of IFNAR1 by WNVKUNS653F was
evident (Figure 1G). By 72 hpi, higher IFNb production occurred
in cultures infected with WTWNVKUN, suggesting that enhanced
expression of IFN-I is not the mechanism of IFNAR1 downregu-
lation by WNVKUNS653F. Loss of IFNAR1 was not associated
with reduced expression of IFNAR mRNA following infection
with WNVKUN or with LGTV (Figure S1D). Together, these results
suggest that antagonism of IFN-I signaling by reducing IFNAR1
occurs post-transcriptionally by a mechanism that involves NS5.
To further determine the role of NS5 in IFNAR1 regulation,
we made clonal HEK293 cell lines that stably express GFP
(negative control), WT NS5 derived from LGTV (as a strong
Figure 1. LGTV, TBEV, and WNV Downregulate IFNAR1
(A) Immunoblot of NS5 and IFNAR1 in HEK293 cells infected with LGTV (MOI 3). IFNAR1 was examined following IP of endogenous protein.
(B) Immunoblot of NS5 and IFNAR2 in HEK293 cells infected with LGTV.
(C) Immunoblot of IFNAR1, IFNAR2, and NS5 following TBEV infection (MOI 3). IFNAR1 was examined following IP of endogenous protein.
(D) Flow cytometry of cell surface IFNAR1 following infection with WNVKUNWT or WNVKUNS653F.
(E) Immunoblot demonstrating increased antagonism of IFNb-dependent signaling (as indicated by levels of pY-STAT1) by WNVKUNS653F compared to
WNVKUNWT. Infected cells were left untreated (no IFNb) or treated with IFNb at each time post-infection for 15 min.
(F) Infectious virus measured by FFU/ml.
(G) IFNb in cell supernatants from (F). measured by ELISA. HPI, hours post infection; error bars, mean ± SD from three independent experiments. See also
Figure S1.
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Figure 2. Downregulation of IFNAR1 Is
Associated with the IFN-I Antagonist Func-
tion of NS5 but Independent of Cholesterol
Redistribution
(A) Immunoblot of pY-STAT1 in stable, clonal
HEK293 cells expressing GFP (control), WT LGTV
NS5, or LGTV NS5W647A. Cells were treated with
1,000 U/ml IFNb for 15 min prior to cell lysis for
immunoblotting.
(B) Immunoblot of GFP and NS5 cell lines at 48 hr
post-transfection with IFNAR1-FLAG or IFNAR2-
HA expression plasmids.
(C) Immunoblot of endogenous IFNAR1 in LGTV-
infected cells treated with cholesterol for 24 or
48 hr.
(D) Immunoblot of endogenous IFNAR1 in
WNVKUNS653F-infected cells treated with choles-
terol for 48 hr.
(E) Immunoblot of GFP and WT NS5 cell lines at
48 hr post-transfection with IFNAR1-FLAG treated
with cholesterol. See also Figure S2.IFN-I antagonist), or LGTVNS5W647A that is unable to suppress
IFN-I signaling (Park et al., 2007). The ability of NS5 to block IFN-I
signaling was confirmed by treating the cells with IFNb and
examining pY-STAT1 (Figure 2A). To examine the effect of NS5
on IFNAR, the cells were transfected with IFNAR1-FLAG or
IFNAR2-HA expression plasmids, and IFNAR expression was
examined at 48 hr post-transfection by immunoblot. Suppres-
sion of pY-STAT1 by WT LGTV NS5 was associated with
reduced IFNAR1 (Figure 2B). In contrast, LGTV NS5 W647A
did not impede IFNb-dependent signal transduction and did
not affect IFNAR1 levels. IFNAR2 was slightly, but equally,
reduced in cells expressing either LGTV NS5-WT or -W647A
(Figure 2B). These results demonstrate that NS5 alone can
reduce IFNAR1 and that this ability is dependent on the function
of NS5 as an IFN-I antagonist.
Viruses typically downregulate IFNAR1 in an IFN-I-indepen-
dent manner via the UPR (Fuchs, 2013). Hallmarks of the UPR
include ER luminal binding protein (BiP) expression, PERK phos-
phorylation, and X-box binding protein 1 (XBP1) mRNA splicing
(Hetz, 2012). These stress events also occur during flavivirus
replication (Ambrose and Mackenzie, 2011), prompting us to
test the role of the UPR in NS5 function. In particular, PERK
expression activates p38 MAP kinase causing phosphorylation
of the degron sequence within IFNAR1 and IFNAR1 degradation
(Liu et al., 2009). However, while knockdown of PERK by siRNA
rescued loss of IFNAR1 following treatment of cells with an
inducer of ER stress, thapsigargin (Figure S2A), it did not rescue
IFNAR1 in cells expressing LGTVNS5 (Figure S2B). Furthermore,
both BiP expression (Figure S2C) and XBP1mRNA splicing (Fig-
ure S2D) were induced by treatment of cells with tunicamycin but
were not increased in LGTV NS5-expressing cells compared to
cells expressing GFP or NS5-W647A. This is consistent with
previous work demonstrating that NS5 from WNV does not
induce these markers of ER stress (Ambrose and Mackenzie,
2011). Thus, NS5 inhibits IFNAR1 expression through mecha-
nisms independent of the UPR.
Previous studies have shown that WNV redistributes choles-
terol from the plasma membrane to sites of virus replication
(Mackenzie et al., 2007). In this study, supplementation of in-64 Cell Host & Microbe 18, 61–74, July 8, 2015 ª2015 Elsevier Inc.fected cells with cholesterol replenished plasma-membrane-
localized cholesterol and partially rescued cellular responses to
IFN-I simulation, suggesting that cholesterol sequestration may
disrupt IFNAR1 localization. Thus, LGTV- or WNVKUNS653F-
infected cells were treated with cholesterol for 24 or 48 hr
(Figures S2E and S2F). In untreated cells, filipin staining for
cholesterol was concentrated at perinuclear sites together with
viral antigen, suggesting that cholesterol was redistributed
from the plasma membrane to sites of flavivirus replication
(particularly evident inWNVKUNS653F-infected cells; FigureS2F).
Cholesterol supplementation increased filipin staining in the
plasma membrane of both uninfected (Figure S2E) and infected
cells (Figure S2F) and caused a slight increase in IFNAR1 in un-
infected cells following 48 hr of treatment (Figure 2C). However,
no rescue of IFNAR1 was observed in cells infected with LGTV
(Figure 2C) or WNVKUNS653F (Figure 2D). In addition, LGTV
NS5-mediated inhibition of IFNAR1 was not substantially
affected by cholesterol treatment (Figure 2E). Thus, NS5-medi-
ated antagonism of IFNAR1 occurs through a mechanism inde-
pendent of cholesterol redistribution.
NS5 Binding to PEPD Is Required for Antagonism
of IFNAR1
To determine the cellular target of NS5, we performed a yeast
two-hybrid analysis of the IFN-I antagonist domain of LGTV
NS5 (residues 355–735; Park et al., 2007) that revealed a putative
interaction with human PEPD (not shown). Colocalization of
LGTV NS5 and endogenous PEPD was observed in LGTV-in-
fected cells by confocal microscopy, suggesting that the two
proteins may interact (Figure 3A). This was confirmed by immu-
noprecipitation (IP) of NS5 produced during virus replication with
endogenous PEPD (Figure 3B). Furthermore, proximity ligation
assays (PLAs) that reveal direct protein-protein interactions
in situ indicated that PEPD and NS5 interacted in the cytosol
of LGTV-infected cells (Figure 3C). Using ectopically expressed
proteins, PEPD interacted with NS5 derived from LGTV, WNV,
or TBEV by IP (Figure S3A). In the case of LGTV, PEPD binding
to NS5 was reduced by mutations in NS5 that disrupt IFN-I
antagonism, including W647A (Figure 3D). This finding was
supported by confocal microscopy that showed increased
spatial separation of NS5 mutants and PEPD compared to WT
NS5, indicative of reduced interactions (Figure S3B). Thus, the
function of LGTV NS5 as an IFN-I antagonist is dependent on
its ability to interact with PEPD. Similarly, the S653F mutation
in WNVKUN NS5 resulted in increased colocalization with PEPD
(Figure S3C), further supporting a role for PEPD interactions in
NS5-mediated antagonism of IFNAR1. However, the differences
observed between WT and S653F NS5 association with PEPD
are small. This finding is expected as WT WNVKUN downregu-
lated IFNAR1 over a delayed period (Figure 1), and WT NS5
has a measureable ability to suppress IFN-I signaling (Laurent-
Rolle et al., 2010). Thus, WT WNVKUN NS5 has considerable
potential to associate with PEPD.
Mapping of the interacting domain on PEPD indicated that
LGTV NS5 bound to PEPD residues 1–255 but not 1–183, sug-
gesting that an interaction domain resided between residues
184–255 (Figure 3E). Further truncation of PEPD narrowed this
domain to residues 216–233 (Figures 3F and 3H). In addition,
NS5 interacted with a second domain contained within PEPD
residues 25–441 (Figures 3F and 3H), but further truncation of
PEPD beyond 256–369 resulted in protein instability and failure
to express, so we could not resolve this domain further (data
not shown). These data suggest that binding of NS5 involves at
least two separate NS5-interacting domains on PEPD. However,
NS5 W647A interacted less with PEPD 1–233 (Figure 2G), impli-
cating the N-terminal half as critical for these interactions.
NS5 Function in IFNAR1 Downregulation Is Required for
Virus Resistance to IFN-I and Virulence in Mice
To determine the relevance of these findings to flavivirus biology,
we used reverse genetics to obtain a virus that could not antag-
onize IFN-I signaling. We initially used the molecular clone of
LGTV tomutate NS5 amino acidsW647A or VI630/631AA, but in-
fectious virus was not rescued after passage. However, reverse
genetics of TBEV (strain Oshima) recovered a virus encoding
NS5 mutated at amino acid D380 previously shown to be
required for IFN-I antagonism (Park et al., 2007). Mutation of
TBEV NS5 at D380A did not change NS5 cellular distribution
when expressed alone (Figure 4A, upper panel), but it did alter
NS5-PEPD colocalization, thus demonstrating a role for D380A
in NS5-PEPD interactions (Figure 4A). TBEV D380A grew to
similar titers as WT TBEV but was more sensitive to the antiviral
effects of IFN-I (Figure 4B) associated with reduced abilities to
downregulate IFNAR1 (Figure 4C), inhibit pY-STAT1 (Figure 4D),
and suppress IFN-I-induced gene expression (Figure 4E). To
determine the impact of PEPD on TBEV replication, cells
depleted of IFNAR1 (Figure S4) or PEPD (see Figures 5 and S5
for characterization) were infected with WT TBEV or TBEV
D380A and treated with IFN-I at 24 hpi (Figure 4F). The sensitivity
of TBEV D380A to IFN-I in control cells (shGFP) was lost in cells
deficient for IFNAR1 or PEPD. Thus, the absence of PEPD com-
pensates for the inability of NS5 to downregulate IFNAR1 and
restores replication of TBEV D380A in the presence of IFN-I
equivalent to that of WT TBEV. TBEV D380A exhibited reduced
virulence in mice as demonstrated by 100% survival following
infection (Figure 4G) associated with reduced serum viremia
(Figure 4H) and delayed entry of the virus to the CNS (Figure 4I).
Virus in the brains of D380A mice was sequenced, but no evi-Cdence of reversion was found. Thus, NS5 association with
PEPD and downregulation of IFNAR1 is critical for virus virulence
by promoting resistance to IFN-I and for establishing early virus
replication and dissemination in vivo.
PEPD Is Required for IFNAR1 Expression
The above findings suggest that PEPD has a role in IFN-I
signaling, although a specific role for PEPD in immunity is not
known. To determine if PEPD is required for IFNAR1 expression,
PEPDwas depleted in HEK293 cells by lentivirus-delivered short
hairpin RNA (shRNA). shRNAs targeting GFP or hypoxia-induc-
ible factor 1a (HIF1a) were used as controls. HIF1a was exam-
ined because it is directly regulated by PEPD enzymatic function
(Surazynski et al., 2008a), and it is a transcription factor with
central roles in inflammatory responses. Specific knockdown
was confirmed by immunoblot (Figure 5A), qRT-PCR of mRNA
expression (Figure S5A), and prolidase activity assays (Fig-
ure S5B). Knockdown of PEPD, but not HIF1a, resulted in loss
of endogenous IFNAR1 (Figure 5A) and a significant reduction
in both ISRE-luciferase expression (Figure 5B) and induction of
ISGs (Figure 5C) following IFNb-stimulation. A similar loss of
IFNAR1 was observed following expression of a single shPEPD
sequence, suggesting this result was not due to off-target effects
of pooled shRNA sequences (Figure S5C). In support of a role for
PEPD in IFNAR1 expression, depletion of PEPD reduced the
accumulation of ectopically expressed IFNAR1-FLAG over
time in both uninfected and LGTV-infected cells (Figures 5D
and S5D). IFNAR2-HA protein levels reduced over time but
were generally not affected by knockdown of PEPD expression
or by LGTV infection (Figures 5D and S5D), suggesting that the
role for PEPD in IFNAR expression is subunit specific. LGTV
replication was not affected by lack of PEPD (Figure S5E).
Together, these results demonstrate that PEPD is required for
both expression of IFNAR1 and the induction of ISGs in response
to IFN-I.
The primary function of PEPD is enzymatic cleavage of di-
peptides. Therefore, we examined the role of PEPD enzymatic
activity in IFN-I responses. Surprisingly, LGTV replication did
not reduce PEPD activity (Figure 5E). Further, expression of
a catalytically inactive PEPD mutant (D287A) (Figure S5F)
augmented IFNb-dependent gene expression to the same extent
as expression of WT PEPD (Figure 5F). Supplementation of
PEPD-deficient cells with the product of PEPD catabolism, Pro
(Figure S5G) or HyPro (data not shown), which rescues some
aspects of PEPD deficiency such as HIF1a stabilization (Sura-
zynski et al., 2008a; Surazynski et al., 2008b), did not restore
IFNb-stimulated luciferase expression. Finally, expression of cy-
tokines expected to be regulated by HIF1a or known to downre-
gulate IFNAR1, including VEGF, IFNB, TNF, or IL1B (Fuchs,
2013), were not significantly altered by low PEPD expression
(Figure S5H). Together, these results suggest that the role of
PEPD in IFNAR1 expression is independent of PEPD enzymatic
activity or HIF1a signaling and implicate a second, non-enzy-
matic role for PEPD in cellular responses to IFN-I.
PEPD Is Required for IFNAR1 Maturation
To further determine the function of PEPD in IFNAR1 expression,
IFNAR1-FLAG was expressed in shGFP and shPEPD cells. As
overexpression of IFNAR1 induces its own lysosomalell Host & Microbe 18, 61–74, July 8, 2015 ª2015 Elsevier Inc. 65
Figure 3. NS5 Interaction with PEPD Is Dependent on NS5 Function as an IFN-I Antagonist
(A) Confocal image of NS5 (red) and endogenous PEPD (green) demonstrating colocalization (yellow) during LGTV replication in HEK293 cells.
(B) IP of PEPD followed by immunoblot of NS5 and PEPD in mock- and LGTV-infected cells at 48 hpi.
(C) Proximity ligation analysis (PLA) of mock- or LGTV-infected cells using anti-PEPD and –NS5 antibodies (green dots indicate interactions). Following PLA, cells
were counterstained to visualize the cellular distribution of NS5.
(D) Streptavidin affinity purification (AP) and immunoblot of PEPD-GFP expressed with WT LGTV NS5 or NS5 mutants defective for IFN-I antagonism. NS5-V5
with no AP tag (capTEV tag) was used to control for specificity of purification.
(legend continued on next page)
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degradation by ER stress (Liu et al., 2009), we inhibited degrada-
tion by treatment with NH4Cl (Figure 6A). This increased expres-
sion of IFNAR1 in shGFP cells while rescue was incomplete in
shPEPD cells, predominantly observed for the lower, partially
glycosylated form. The glycosylation of IFNAR1 as previously
described (Ling et al., 1995) was confirmed by the relative sensi-
tivity of the mature fully glycosylated form and the immature,
partially glycosylated form to PNGase and EndoH respectively
(Figures 6B and 6C). These results suggest that protection of
IFNAR1 from degradation is not the major mechanism of PEPD
function. In support of this, the total half-life of IFNAR1-FLAG
was not different between shGFP and shPEPD cells treated
with cyclohexamide (CHX) to inhibit new protein synthesis (Fig-
ures 6D and 6E). However, maturation of IFNAR1 in shGFP cells
as indicated by the increased ratio of fully glycosylated:partially
glycosylated IFNAR1 over time was compromised in the
absence of PEPD (Figure 6F). This failure of IFNAR1 to transition
from high mannose N-linked carbohydrate (EndoH-sensitive) to
complex N-linked oligosaccharide (EndoH-resistant) suggests
that PEPD may function in IFNAR1 biosynthesis by facilitating
its trafficking through the ER-to-golgi network.
PEPD Deficiency in Humans Is Associated with Defects
in IFNb-Stimulated Responses
Our results identifying PEPD as a central regulator of cellular
responses to IFN-I suggest that defects in type I IFN signaling
could contribute to the clinical features of PD. To address
this possibility, we examined primary fibroblasts from two
individual PD patients with different mutations resulting in
premature translation termination (768C > G) or alternative
splicing (IVS7-1G > A) of PEPD. Visualization of endogenous
IFNAR1 using an antibody against the intracellular IFNAR1
domain in fibroblasts from control patients showed a diffuse
speckling throughout unstimulated cells (Figure 7A). Following
1 hr stimulation with IFNb, IFNAR1 localized to the nucleus,
which is consistent with previous observations (Subramaniam
and Johnson, 2004). In contrast, in the absence of exogenous
IFNb stimulation of PD fibroblasts, IFNAR1 was localized in
distinct cytoplasmic puncta or to the nucleus (Figure 7A). This
aberrant localization was associated with low levels of total
IFNAR1 at the protein level (Figure 7B), which was not attribut-
able to altered expression of IFNAR1 mRNA (Figure 7C).
Further, phosphorylation of both STAT1 and STAT2 in response
to IFNb was reduced in PD fibroblasts compared to control
cells (Figure 7D). IFNb-stimulation of fibroblasts from four con-
trols and four PD patients (adding one additional splicing muta-
tion IVS11+1G > C) demonstrated 10-fold or greater reduction
in IFN-I-induced ISG mRNA expression in three of four patients
(Figure 7E). However, induction of ISG mRNA expression in the
fibroblasts harboring a premature stop codon in pepd (768C >
G) was similar to controls in five of six genes analyzed, despite
low pY-STAT1 following IFNb stimulation (see Discussion).
Nevertheless, these results demonstrate that defects in IFN-I(E and F) Mapping of the NS5 binding domain in PEPD by AP and immunoblot. F
PEPD-GFP, and cell lysates were subjected to AP using streptavidin-coated bea
(G) Streptavidin AP of interactions between WT or W647A LGTV NS5 and PEPD
(H) Summary of findings in (E) and (F). Asterisks (*) indicate positions of reported
See also Figure S3.
Csignaling are associated with low IFNAR1 in humans with ge-
netic PD.
Interestingly, while the general ability of PD fibroblasts to
respond to IFN-I stimulation was compromised as measured
by pY-STAT1, the basal expression of ISG mRNA was elevated
above that of control fibroblasts in a highly gene-specific
manner. Elevated ISGs included RSAD2 (also known as viperin)
and CXCL10, but not IRF7, ISG15, ISG54, or ISG56 (Figure 7F).
Fibroblasts from patients with PD also expressed high basal
levels of viperin at the protein level, and viperin expression was
further increased following IFNb stimulation (Figure 7G). The
basal elevation of ISG mRNA did not appear to be associated
with chronic IFN-I expression as constitutive phosphorylation
of STAT1 was not evident in PD fibroblasts (Figure 7D), most ca-
nonical ISGs were not elevated above controls, and IFNBmRNA
expression in PD fibroblasts was not different from controls
(Figure 7F). To assess ISG expression, we used Agilent whole-
genome microarrays to identify differentially expressed genes
(DEGs) relative to control human fibroblasts (n = 4 per group;
fold change > j1.5j, q < 0.05) (Table S1). Hierarchical clustering
on expression data from 104 ISG probes of interest relative to
normal donors identified increased expression of select ISGs,
including STAT1 and STAT2, TLR3, DDX58 (RIG-I), IFIH1
(MDA5), MX1 and MX2, and inflammatory cytokines such as
IL32 and IL1RN (Figure S7; Table S2). Thus, PEPD may nega-
tively regulate the basal expression of a subset of ISGs in addi-
tion to its role in IFNAR1 expression. Together, these studies
reveal PEPDmutations as a source of primary immune dysfunc-
tion in humans associated with defects in type I IFN signaling and
innate immunity.
DISCUSSION
Several viruses evade ISG expression by preventing expression
of the IFN-I receptor, most commonly through loss of IFNAR1.
In most cases, downregulation of IFNAR1 occurs indirectly as
a result of virus replication inducing ER stress or TLR signaling
that trigger phosphorylation and degradation of the receptor
(Fuchs, 2013; Liu et al., 2009; Qian et al., 2011). However, by
examining the mechanisms of flavivirus IFN-I antagonism, we
reveal a point of control of IFNAR1 expression that is governed
by PEPD and antagonized by the NS5 protein from LGTV,
TBEV, and likely WNV. Evidence supporting a role for PEPD in
IFNAR1 expression includes (1) NS5 interactions with PEPD
were required for antagonism of IFNAR1, (2) PEPD was required
for optimal IFNAR1 expression and ISG induction following IFN-I
stimulation, (3) PEPD was required for expression of IFNAR1
without affecting its rate of degradation, and (4) the absence of
PEPD completely complemented the defect in IFN-I antagonism
by TBEV D380A. Furthermore, the ability to manipulate PEPD
and downregulate IFNAR1 was an important virus virulence
factor in vivo. Finally, we demonstrated that PEPD is relevant
to IFN-I-dependent signaling in human biology, as primaryull-length LGTV NS5-V5capTEV was coexpressed with truncation mutants of
ds followed by immunoblotting with the indicated antibodies.
residues 1–233.
residues responsible for coordinating metal ion binding (enzymatic active site).
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Figure 4. NS5 Function in IFNAR1 Downregulation Is Required for TBEV Resistance to IFN-I and Virulence in Mice
(A) Co-localization of WT or D380A NS5 from TBEV (Oshima) (red) with PEPD-GFP (green). Upper panel shows the individual proteins expressed alone; lower
panel shows NS5 colocalization with PEPD and nuclei counterstained with DAPI.
(B) Virus titers inmouse neuroblastoma cells infectedwith TBEVWT or D380A (MOI = 1) and then left untreated or treatedwith 500 U/ml IFNa at 24 hpi (mean ± SD,
three independent experiments).
(C) Immunoblot of NS3 (as a marker of infection) and IFNAR1 in HEK293 cells infected with WT or D380A TBEV (MOI 5). IFNAR1 was examined following IP of
endogenous protein.
(legend continued on next page)
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fibroblasts from patients with prolidase deficiency had signaling
defects in response to IFNb-stimulation. Together, these find-
ings expand our understanding of how IFNAR1 is regulated
and therefore extend the paradigm of type I IFN signaling.
Our results suggest a model (Figure S6) where TBEV, LGTV,
and WNV target PEPD to prevent the accumulation of IFNAR1
to antagonize IFN-I signaling. We propose that this occurs
through inhibition of IFNAR1 intracellular trafficking and glyco-
sylation as opposed to degradation. In support of this, we could
not rescue IFNAR1 by inhibition of lysosomal or proteasomal
degradation pathways, and PEPD did not affect IFNAR1 half-
life. However, the precise mechanism whereby PEPD facilitates
IFNAR1 expression is currently unknown and requires further
biochemical studies to fully understand both IFNAR1 biosyn-
thesis and the potential function of PEPD. The role of PEPD in
IFN-I responses is clearly complex and may involve more than
one function. For example, our studies have not ruled out a
role for PEPD in IFNAR1 translation. Further, it is possible that
NS5 fromdifferent flaviviruses has additional roles in IFN-I antag-
onism, particularly because LGTV NS5 only requires a central
domain within the RNA-dependent RNA polymerase (RdRP) to
suppress signaling, whereas TBEV NS5 requires both the N ter-
minus and the central RdRP domain (Laurent-Rolle et al., 2010).
During virus replication, the function of NS5 in IFNAR1 antago-
nism is independent of the induction of ER stress by the small
transmembrane nonstructural proteins (NS4A and NS4B) (Am-
brose and Mackenzie, 2011) or cholesterol redistribution from
the plasma membrane (Mackenzie et al., 2007). However, these
events most likely synergize with NS5 during virus replication to
efficiently antagonize signaling.
In humans, PD is considered a disease of connective tissue,
although its clinical manifestations are not explained by lack of
available Pro or abnormalities in collagen production (Hechtman,
2006). PD patients often experience recurrent deep skin ulcera-
tion complicated by bacterial or fungal infection that can become
systemic, as well as frequent pulmonary infections including
otitis media, sinusitis, and pneumonia (Caselli et al., 2012).
Furthermore, individual patients have been reported to have
cytomegalovirus or herpesvirus infections (Hechtman, 2006).
Our findings suggest that PEPD-dependent regulation of IFN-I
responses may contribute to these clinical findings of infection.
However, although PD fibroblasts had low expression of
IFNAR1, this is not the equivalent of a total absence of IFNAR1,
because only 10% occupancy of surface IFNAR is required to
signal and mount an antiviral response following IFN-I stimula-
tion (reviewed in Fuchs, 2013). Therefore, antiviral responses
that require low density of IFNAR may not be overtly compro-
mised in PD patients. Further, the observed basal expression
of antiviral ISGs may confer some resistance to viral infection,
while simultaneously increasing susceptibility to bacterial infec-(D) IFA of STAT1 phosphorylation (pY-STAT1) in neuroblastoma cells mock infecte
cells were visualized by staining with an anti-TBEV polyclonal antibody and nucl
(E) ISRE-luciferase assay in neuroblastoma cells infectedwithWT or D380A TBEV
experiments).
(F) Growth curves of WT and D380A TBEV in shGFP (control), shIFNAR1, or shPE
lines indicate WT TBEV titer at 48 and 72 hpi for comparisons. Mean ± SD, three
(G–I) Balb/c mice were infected subcutaneously with 1,000 pfu WT (n = 15) or D3
(H) or brain (I) of infected mice (N = 6/group). Grey line indicates limit of detectio
Ctions, as recently suggested for two ISGs, oxysterol 25-hydrox-
ycholesterol (Reboldi et al., 2014) and the methyltransferase
Setdb2 (Schliehe et al., 2015). PEPD is also required for early
trafficking events of influenza virus in endosomes (Pohl et al.,
2014), which may explain the lack of severe influenza in PD
patients, although PEPD was clearly antiviral in the context of
IFN-I-dependent inhibition of TBEV replication. Therefore, the
roles of PEPD in innate immunity and virus infection are multi-
faceted.
Our work suggests that PEPD has at least two functions: its
dipeptidase activity and a dipeptidase-independent function in
regulating cellular responses to IFN-I. Therefore, clinical vari-
ability of PD may be associated with specific mutations that
affect one or both of these roles. This association is difficult to
ascertain here, as all patients examined had a complete loss of
PEPD resulting from mRNA splicing defects or premature trans-
lation termination, in contrast to an intact gene containing single
amino acid mutations. In addition, fibroblasts from one patient
(768C > G) had low IFNAR1 and STAT phosphorylation, but
expression of ISG mRNA was largely comparable to controls.
However, these specific fibroblasts were unique in that (1) the
mutation in PEPD was the only one represented in our study
with the premature STOP codon (Y256STOP) compared to
mRNA splicing mutations in the remaining three PD patients,
and (2) they expressed high basal levels of STAT1 with IFNAR1
localization in the nucleus. Elevated levels of STAT1 positively
regulate ISG expression independent of pY-STAT1 (Cheon and
Stark, 2009). Furthermore, translocation of cell surface receptors
to the nucleus can positively regulate gene expression, as shown
for the insulin-like growth factor 1 receptor (Sehat et al., 2010), or
the epidermal growth factor receptor that promotes epigenetic
modifications (Chou et al., 2014). Thus, both IFNAR1 nuclear
localization (Subramaniam and Johnson, 2004) and high
STAT1 expression could contribute to ISG expression following
IFN-I stimulation, despite the low activation of pY-STAT1. Thus,
understanding the contribution of specific PEPD polymorphisms
to IFN-I signaling in humans is an important future research
direction.
Paradoxically, primary PD fibroblasts exhibit basal upregula-
tion of ISG mRNA in a highly gene-specific manner despite
impaired responses to IFN-I stimulation. This finding may be
relevant to the clinical manifestations of PD, as approximately
10% of PD patients are diagnosed with SLE or an SLE-like
syndrome. Indeed, some of the pathological aspects of PD
(including CNS vasculitis, angiopathy of small blood vessels,
loss of C1q and elevated immunoglobulin levels) are remi-
niscent of other human genetic diseases termed ‘‘interferono-
pathies’’ associated with elevated ISG expression, such as
Aicardi-Goutie`res syndrome, cases of SLE with complement
deficiency and STING-associated vasculopathy with onset ind or infected withWT or D380A TBEV (MOI = 1) and treated with IFNa. Infected
ei counterstained with DAPI.
(MOI = 1) and treatedwith 500U/ml IFNa for 6 hr (mean ±SD, three independent
PD cells in the absence or presence of 500 U/ml IFNa added at 24 hpi. Dashed
independent experiments.
80A TBEV (n = 10) and monitored for survival (G). Virus was titered from serum
n.*p% 0.05; ****p < 0.0001; n.s., not significant. See also Figure S4.
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Figure 5. PEPD Is Required for IFNAR1 Expression and ISG Expression in Response to IFN-I Stimulation
(A) Immunoblot of lysates from cells expressing shRNA specific for GFP, PEPD or HIF1a demonstrating reduced target protein expression and reduced IFNAR1 in
the absence of PEPD. HIF1a was visualized following treatment of cells with CoCl2 and MG132 to induce HIF1a expression and simultaneously inhibit its
degradation resulting in appearance of highly ubiquitinated protein as a smear. IFNAR1 was examined following IP of endogenous protein.
(B) ISRE-luciferase assay performed in cells shown in (A). Mean ± SD, three independent experiments.
(C) qRT-PCR for ISG expression in shGFP and shPEPD cells treated with 1,000 U/ml IFNb for 6 hr (mean ± SD, three independent experiments; *p < 0.05;
***p < 0.001).
(D) Immunoblot of IFNAR1 and IFNAR2 expression in uninfected (mock) or LGTV-infected shGFP cells () or shPEPD cells (+). Cells were transfected with
IFNAR1-FLAG or IFNAR2-HA for 24 hr prior to infection. Infection is indicated by immunoblot for NS5. HPI, hours post-infection.
(E) PEPD activity assay following LGTV infection demonstrating no loss of conversion of Gly-Pro dipeptides to free Pro in virus-infected cells (mean ± SD, three
independent experiments).
(F) ISRE-luciferase assay performed in HEK293 cells transfected with expression plasmids for GFP, WT PEPD, or PEPD-D287A following treatment with
1,000 U/ml IFNb for 6 hr (mean ± SD, three independent experiments). Equal expression of WT or D287A PEPD was shown by immunoblot. See also Figure S5.infancy (SAVI) (reviewed in Crow, 2015). There is currently no
evidence that the ISG expression in patients with PD is driven
by aberrant production of IFN-I, and therefore, the mechanisms
of ISG regulation may be different between PD and the various
interferonopathies. However, IFN-I production in patients with70 Cell Host & Microbe 18, 61–74, July 8, 2015 ª2015 Elsevier Inc.PD during an immune response may result in abnormally high
levels of certain ISGs as we observed for RSAD2/viperin, which
may be detrimental.
In summary, this work reveals PEPD as an important regu-
lator of IFNAR1 and cellular responses to IFN-I. The fact that
Figure 6. PEPD Is Required for IFNAR1 Maturation
(A) Immunoblot of IFNAR1-FLAG in shGFP and shPEPD cells at 48 hr post-transfection and treated with DMSO or 25 mM NH4Cl for 4 hr.
(B and C) Examination of IFNAR1-FLAG glycosylation by sensitivity to (B) PNGase or (C) EndoH.
(D) Immunoblot of IFNAR1-FLAG half-life in shGFP and shPEPD cells treated with 20 mg/ml CHX and sampled at the times indicated.
(E) Quantification of IFNAR1-FLAG band intensity in (D), normalized to time 0 and actin levels.
(F) Quantification of the ratio of upper (mature, fully glycosylated) to lower (immature, partially glycosylated) bands of IFNAR1 in (D). Data are shown from one
experiment of three performed, and represent mean ± SD from three exposures. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, two-way ANOVA with Sidaks
multiple comparison post-test. See also Figure S6.both TBEV and WNV appear to target IFNAR1 through PEPD
suggests that manipulation of this pathway may lead to
development of broadly acting antiviral therapies. Moreover,
we have identified PD in humans as a primary immune defi-
ciency associated with defects in IFN-I signaling. However,
PD appears to involve a complex phenotype with high basal
ISG signatures that may confer an inflammatory component
to disease. Hence, this work provides additional research di-
rections in understanding the immunopathology associated
with PD and the potential for therapeutic intervention. Finally,
the central role of IFNAR1 in human autoimmunity and tumor
surveillance and eradication suggests that tactics to manipu-Clate PEPD may have therapeutic relevance in a variety of
medical applications.EXPERIMENTAL PROCEDURES
Cell Culture and Viruses
HEK293, Vero cells, BHK-21 and mouse neuroblastoma NA cells (ATCC), and
primary human fibroblasts were cultured in DMEM supplemented with 10%
(vol/vol) fetal calf serum (GIBCO), 100 units/ml penicillin, and 100 mg/ml strep-
tomycin (Life Technologies) in an atmosphere of 5% CO2 at 37
C. The gener-
ation of primary human fibroblasts is described in Supplemental Experimental
Procedures. All cell lines were routinely tested for mycoplasma and used at
passage numbers <20 for standard lines and <10 for primary fibroblasts.ell Host & Microbe 18, 61–74, July 8, 2015 ª2015 Elsevier Inc. 71
Figure 7. Fibroblasts from PEPD-Deficient Patients Have Reduced Responses to IFNb Associated with Low IFNAR1 Expression
(A) IFA of dermal fibroblasts from a control (Ctrl) patient or two PD patients harboring different mutations (768C > G or IVS7-1G > A). IFNAR1 is green and DAPI
staining of the nucleus is blue. Scale bar, 20 mM.
(B) Immunoblot of IFNAR1 for patient samples represented in (A).
(C) qRT-PCR of IFNAR1 mRNA expression in fibroblasts from four patients with PD, normalized to HPRT mRNA and expressed as fold difference from control
fibroblasts (mean ± SD, from three experiments performed in triplicate).
(D) Immunoblot verifying the absence of PEPD in patient samples and demonstrating reduced pY-STAT1 and pY-STAT2 following 15 min IFNb stimulation.
(legend continued on next page)
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The following viruses were used in this study: LGTV strain TP21 (from A. Plet-
nev, NIAID, NIH), TBEV strain Sofjin (M. Holbrook, NIAID, NIH), WNV strain
NY99 (from the WRCEVA, UTMB), and WNVKUN and WNVKUN:NS5 S653F
(A. Khromykh, U. Queensland, Australia), as previously described (Laurent-
Rolle et al., 2010). Flavivirus stocks were propagated and titrated by immuno-
focus assay on Vero cells (Laurent-Rolle et al., 2010). MOI is represented as
focus-forming units (FFU) per cell. Construction and recovery of recombinant
TBEV (Oshima) and infection of mice are described in Supplemental Experi-
mental Procedures.
Prolidase-Deficient Patients and Data
Prolidase-deficient patients were enrolled on an NIAID Institutional Review
Board (IRB) approved protocol (10-H-0126; NCT00001355) or in an Italian
Ethical Committee approved study (Prot22/CE, Pavia). The accession number
for raw microarray data is GEO: GSE64387.
Stable and Transient Knockdown by RNAi
Stable, clonal shGFP, shPEPD, and shHIF1a HEK293 cells were generated
using Lentivirus pools encoding siRNAs from Santa Cruz Biotechnology
specific for GFP (sc-45924-V), PEPD (sc-97436-V), or HIF1a (sc-35561-V).
Following infection with lentiviruses in the presence of 8 mg/ml polybrene,
cells were incubated for 48 hr prior to selection with 2 mg/ml puromycin.
Lentivirus encoding the tet-inducible shRNA sequence for non-targeting
(CCTAAGGTTAAGTCGCCCT) or PEPD (ATCAGCAAGTTCGAAGTCA) were
made using the pLCTV-tTR-KRAB-inducible system and subcloning plasmid
pLVTHM (Addgene#12247), packaging plasmid psPAX2 (Addgene#12260),
and VSV-G envelope expressing plasmid pMD2.G (Addgene#12259), kindly
supplied by Dr. D. Trono and P. Aebischer (Szulc et al., 2006).
Small interfering RNA (siRNA) was used to knockdown EIF2AK3 (PERK) in
293 cells. SMARTpool siRNA containing four target sequences against human
PERK mRNA (L-004883), and a nonspecific control sequence (D-001810-10),
were obtained from Thermo Scientific. Briefly, cells grown in 24-well plates
were transfected with 15 pmol of PERK or nonspecific control siRNA using
Lipofectamine RNAiMAX reagent (Invitrogen). After 48 hr, cells were then
transfected with IFNAR-FLAG expression construct using Lipofectamine LTX
reagent. Protein lysates were collected at 24 hr post-transfection/72 hr post-
knockdown. In some experiments, cells were treated with 1 mM thapsigargin
for 2 hr (Sigma) prior to collecting protein lysates. Knock down of PERK was
determined by immunoblotting with anti-PERK rabbit monoclonal antibody
(Cell Signaling Technology).
Plasmids, Transfection, Reagents, Antibodies, Antibody-Based
techniques
Reagents, antibodies, flow cytometry, IP and affinity purification of interacting
proteins, Xbp-1 splicing assay, luciferase reporter assays, prolidase activity
assays, IFNb ELISA, immunofluorescence, and PLAs are described in the Sup-
plemental Experimental Procedures.
Quantitative RT-PCR, Microarray and Statistical Analysis
RT-qPCR, RNA preparation and oligonucleotide microarray processing, mi-
croarray data processing and analysis, and general statistical analysis are
described in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, two tables, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.chom.2015.06.007.(E) qRT-PCR of ISGmRNA expression following 6 hr stimulation with 100 U IFNb i
point representing a different individual patient (mean from at least three expe
transcript in each sample and is represented as fold induction over the same sa
(F) qRT-PCR of basal ISG mRNA expression without addition of exogenous IF
expression was normalized to HPRT transcript in each individual sample and is
**p < 0.01 and ****p < 0.0001, determined by one-way ANOVA with Sidak’s post
(G) Rsad2 (viperin) protein expression in control andPDfibroblasts unstimulated or
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